GlaxoSmithKline’s former chief executive Andrew Witty was yesterday announced as the new CEO of Optum – a US payer organisation which includes pharmacy benefits manager OptumRx.

Former GSK CEO Sir Andrew Witty, and his former drug development chief, Moncef Slaoui have both lined up new jobs as life science investors. The announcements yesterday are part of a growing trend ...

UnitedHealth Group (NYSE: UNH) has spent a significant amount of time in the sick bay for the first half of 2025, but it’s ...

U.S. Senator Maggie Hassan said on Friday she is launching an investigation into British pharmaceutical giant GlaxoSmithKline's decision to discontinue a widely used asthma inhaler for children.

GSK plc (NYSE: GSK) is one of the 11 best European stocks to invest in. On June 24, the company announced receipt of FDA approval for a 200 mg/mL autoinjector of Benlysta (belimumab) for the ...

GSK, Novartis, Lilly among Big Pharmas celebrating International Women’s Day 2025 Several of the companies tied their Pride celebrations to their ongoing scientific work.

Andrew Schulz is set to play Dan Hibicki in Legendary's 'Street Fighter' movie.

Congressman Mike Flood took the time Thursday to honor KETV's Andrew Ozaki on the U.S. House floor. In his speech, the Republican called Ozaki a "giant in Nebraska journalism." ...

To tackle this, Save the Children and GSK are offering a $100,000 innovation grant to support groundbreaking community ideas that demonstrate potential to increase immunisation coverage sustainably.

GSK's regulatory filing for expanded use of RSV vaccine, Arexvy, in adults aged 18 years and older has been accepted for review by the EMA.

GSK's marketing application for linerixibat, targeting cholestatic pruritus in PBC patients, gains EMA acceptance based on phase III success.